Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib was subsequently approved for the clinical use as a front-line treatment for newly diagnosed multiple myeloma patients and for the treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this drug has become the staple of treatment. The approval of bortezomib by the US Food and Drug Administration (FDA) represented a significant milestone as the first proteasome inhibitor to be implemented in the treatment of malignant disease. Bortezomib has shown a positive clinical benefit either alone or as a part of combination therapy to induce chemo-/radio-sensitization or overcome drug resistance. One of the major mechanisms of bortezomib associated with its anticancer activity is through upregulation of NOXA, which is a proapoptotic protein, and NOXA may interact with the anti-apoptotic proteins of Bcl-2 subfamily Bcl-X(L) and Bcl-2, and result in apoptotic cell death in malignant cells. Another important mechanism of bortezomib is through suppression of the NF-κB signaling pathway resulting in the down-regulation of its anti-apoptotic target genes. Although the majority of success achieved with bortezomib has been in hematological malignancies, its effect toward solid tumors has been less than encouraging. Additionally, the widespread clinical use of bortezomib continues to be hampered by the appearance of dose-limiting toxicities, drug-resistance and interference by some natural compounds. These findings could help guide physicians in refining the clinical use of bortezomib, and encourage basic scientists to generate next generation proteasome inhibitors that broaden the spectrum of efficacy and produce a more durable clinical response in cancer patients. Other desirable applications for the use of proteasome inhibitors include the development of inhibitors against specific E3 ligases, which act at an early step in the ubiquitin-proteasome pathway, and the discovery of less toxic and novel proteasome inhibitors from natural products and traditional medicines, which may provide more viable drug candidates for cancer chemoprevention and the treatment of cancer patients in the future.
The Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, and Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan, USA. doup@karmanos.org
D
D
Chen
M
M
Frezza
S
S
Schmitt
J
J
Kanwar
Q P
QP
Dou
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011480:Protease Inhibitors / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex
Mol Cancer Ther. 2008 Sep;7(9):2866-75
18790767
J Clin Oncol. 2010 May 1;28(13):2259-66
20368561
Lung Cancer. 2010 Jun;68(3):420-6
19692142
Clin Cancer Res. 2007 Mar 15;13(6):1762-8
17363530
Mol Cancer Ther. 2002 Dec;1(14):1243-53
12516957
Br J Haematol. 2001 Apr;113(1):126-35
11328292
Science. 1998 Aug 28;281(5381):1322-6
9735050
Hematology Am Soc Hematol Educ Program. 2005;:220-5
16304384
Semin Oncol. 2001 Dec;28(6):626-33
11740821
Expert Opin Investig Drugs. 2009 Jul;18(7):957-71
19505187
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3850-5
10725400
Cancer Res. 2004 Jun 1;64(11):3949-57
15173007
Clin Cancer Res. 2003 Mar;9(3):1136-44
12631619
J Biol Chem. 2001 Apr 20;276(16):13322-30
11278274
Cancer Control. 2003 Sep-Oct;10(5):361-9
14581890
Future Oncol. 2008 Apr;4(2):149-68
18407730
Cell. 1994 Oct 7;79(1):13-21
7923371
Blood. 2009 Jul 30;114(5):1046-52
19436050
Clin Cancer Res. 2007 Feb 15;13(4):1208-15
17317831
Clin Genitourin Cancer. 2007 Mar;5(4):278-83
17553208
Apoptosis. 2003 Aug;8(4):337-43
12815276
Br J Haematol. 2010 May;149(4):550-9
20331453
Pharm Res. 2009 Aug;26(8):1874-80
19421843
Drug Resist Updat. 2002 Dec;5(6):249-58
12531181
Oncologist. 2003;8(6):508-13
14657528
Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):14-21
15688598
Cancer Res. 2007 Mar 15;67(6):2783-90
17363600
Curr Protein Pept Sci. 2010 Sep;11(6):459-70
20491623
Blood. 2005 Apr 15;105(8):3058-65
15626743
Nat Cell Biol. 2005 Aug;7(8):758-65
16056267
Pharm Res. 2009 Nov;26(11):2438-45
19714451
N Engl J Med. 2003 Jun 26;348(26):2609-17
12826635
Clin Cancer Res. 2010 Feb 1;16(3):814-24
20103673
Am J Clin Oncol. 2001 Oct;24(5):481-5
11586100
Cancer Res. 2005 Jul 15;65(14):6282-93
16024630
Blood. 1999 May 1;93(9):3044-52
10216101
Science. 1995 Aug 4;269(5224):682-5
7624798
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
Br J Haematol. 2009 Jan;144(2):169-75
19036114
Mol Cell Biol. 2004 Nov;24(22):9695-704
15509775
Cancer Res. 2001 Feb 15;61(4):1280-4
11245420
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3263-8
12626766
Cell Mol Life Sci. 2004 Jul;61(13):1596-600
15224184
N Engl J Med. 2008 Aug 28;359(9):906-17
18753647
J Biol Chem. 2007 May 25;282(21):15498-505
17403672
J Clin Oncol. 2006 Oct 20;24(30):4867-74
17001068
Genes Dev. 1997 Apr 15;11(8):957-72
9136925
Cancer Res. 2006 May 1;66(9):4758-65
16651429
Clin Cancer Res. 2008 Mar 15;14(6):1649-57
18347166
J Pharmacol Exp Ther. 2008 Aug;326(2):423-31
18502982
Bioessays. 2000 May;22(5):442-51
10797484
Clin Transl Oncol. 2006 May;8(5):313-7
16760005
Br J Haematol. 2005 Jun;129(6):755-62
15953001
Cancer Res. 2001 Apr 1;61(7):3071-6
11306489
Clin Lymphoma Myeloma. 2008 Oct;8(5):315-7
18854289
Br J Haematol. 2005 Jun;129(6):776-83
15953004
Breast Cancer Res. 2003;5(1):1-7
12559038
Cancer Res. 2002 Sep 1;62(17):4996-5000
12208752
Mar Drugs. 2010 Mar 25;8(4):835-80
20479958
J Urol. 2007 Dec;178(6):2378-83; discussion 2383-4
17936848
Clin Cancer Res. 2002 Aug;8(8):2505-11
12171876
J Clin Oncol. 2008 Oct 10;26(29):4777-83
18645194
Blood. 2009 Jun 4;113(23):5927-37
19190249
Clin Cancer Res. 2004 Jun 1;10(11):3839-52
15173093
Cancer Res. 2008 Sep 15;68(18):7283-92
18794115
Mol Immunol. 2002 Oct;39(3-4):147-64
12200047
J Clin Oncol. 2005 Sep 1;23(25):6107-16
16135477
FEBS Lett. 1997 Dec 22;420(1):25-7
9450543
Nat Clin Pract Oncol. 2006 Jul;3(7):374-87
16826218
Bioorg Med Chem. 2009 Mar 15;17(6):2175-80
19022674
Annu Rev Biochem. 1996;65:801-47
8811196
Nature. 2009 Apr 9;458(7239):732-6
19360080
Cancer Res. 2006 Nov 1;66(21):10425-33
17079463
Cell Death Differ. 1999 Apr;6(4):303-13
10381632
Science. 2000 May 12;288(5468):1053-8
10807576
Br J Haematol. 2009 Mar;144(6):895-903
19170677
Mar Drugs. 2010 Oct 15;8(10):2702-20
21116415
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9
12391322
Clin Cancer Res. 2006 May 15;12(10):2955-60
16707588
J Clin Oncol. 2006 Feb 20;24(6):937-44
16418495
J Clin Oncol. 2005 Feb 1;23(4):676-84
15613699
Cancer Cell. 2004 May;5(5):417-21
15144949
J Clin Oncol. 2002 Nov 15;20(22):4420-7
12431963
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4
17875757
Cancer. 2006 Dec 1;107(11):2688-97
17075878
Clin Cancer Res. 2009 Jun 1;15(11):3820-6
19458051
Drug Resist Updat. 1999 Aug;2(4):215-223
11504494
Ann Oncol. 2006 May;17(5):813-7
16403809
J Biol Chem. 2004 Mar 19;279(12):11680-5
14701837
Nat Rev Drug Discov. 2004 Jan;3(1):17-26
14708018
Urology. 2010 Apr;75(4):793-8
19800672
Leukemia. 2009 Sep;23(9):1679-86
19369963
Cell Mol Life Sci. 1999 Dec;56(11-12):908-17
11212325
Br J Cancer. 2006 Oct 23;95(8):961-5
17047643
Cancer Res. 1998 Oct 1;58(19):4342-8
9766662
Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93
11316563
Cell. 1998 Feb 6;92(3):367-80
9476896
Clin Cancer Res. 2007 Jun 15;13(12):3642-51
17575229
J Clin Oncol. 2005 Feb 1;23(4):667-75
15613697
J Clin Oncol. 2004 Sep 15;22(18):3720-5
15365068
Cancer Treat Rev. 2003 May;29 Suppl 1:3-9
12738238
Cancer Res. 2006 Jun 15;66(12):6379-86
16778216
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6111-8
15447997
Curr Opin Cell Biol. 1995 Apr;7(2):215-23
7612274
Cancer Res. 2006 Apr 1;66(7):3754-63
16585202
Cancer Res. 1999 Jun 1;59(11):2615-22
10363983
J Clin Oncol. 2006 Nov 1;24(31):5025-33
17075122
Cancer Res. 2007 May 1;67(9):4303-10
17483343
Br J Haematol. 2009 Aug;146(3):270-81
19500098
J Mol Biol. 1993 Dec 20;234(4):932-7
8263938
Drugs. 2009;69(7):859-88
19441872
Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2253-8
14982996
Int J Cancer. 2002 Mar 10;98(2):161-6
11857402
Ann Oncol. 2007 Jan;18(1):116-121
16971665
Br J Haematol. 2007 Jan;136(1):106-10
17222199
Drug Resist Updat. 2006 Dec;9(6):263-73
17197231
J Biosci. 2006 Mar;31(1):137-55
16595883
J Cell Biochem. 2001 Apr 2-27;82(1):110-22
11400168
Cancer Biol Ther. 2006 Jul;5(7):745-8
16861900
Blood. 2007 Nov 1;110(9):3281-90
17591945
Clin Lung Cancer. 2005 Oct;7 Suppl 2:S64-6
16250930
Exp Hematol. 2008 Oct;36(10):1278-84
18562081
Clin Cancer Res. 2006 Feb 15;12(4):1270-5
16489083
Br J Haematol. 2004 Oct;127(2):165-72
15461622
Leukemia. 2002 Apr;16(4):433-43
11960320
J Biol Chem. 1999 Aug 6;274(32):22123-6
10428771
Am J Health Syst Pharm. 2008 Jul 1;65(13):1221-31
18574011
Cancer Res. 2010 May 1;70(9):3606-17
20388782
Histol Histopathol. 2008 Apr;23(4):487-96
18228206
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10976-83
10500111
Nature. 1997 Apr 3;386(6624):463-71
9087403
Biochem Pharmacol. 2003 Sep 15;66(6):965-76
12963483
Exp Hematol. 2009 Jul;37(7):831-7
19426847
Curr Opin Chem Biol. 2002 Aug;6(4):493-500
12133726
Br J Haematol. 2009 Mar;144(6):887-94
19183191
Cancer Invest. 2007 Dec;25(8):733-7
17952740
Cancer Res. 2005 May 1;65(9):3828-36
15867381
Breast Cancer Res. 2007;9(6):R80
18300387
Nature. 2003 Dec 18;426(6968):895-9
14685250
Cancer Res. 2005 Jul 15;65(14):6294-304
16024631
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7071-5
2205851
Blood. 2008 Sep 15;112(6):2489-99
18565852
Clin Cancer Res. 2009 Nov 15;15(22):7085-91
19903785
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19488-93
18042711
IDrugs. 2002 Aug;5(8):828-34
12802699
Cancer Res. 2006 Oct 1;66(19):9636-45
17018621
J Clin Oncol. 2007 Sep 1;25(25):3892-901
17679727
Clin Cancer Res. 2001 May;7(5):1419-28
11350913
Nat Med. 1997 Feb;3(2):231-4
9018245
Oncogene. 2009 Nov 12;28(45):3983-96
19734940
Leukemia. 2008 Dec;22(12):2247-56
18769451
Cancer Lett. 2010 Jun 1;292(1):48-53
19962231
Cancer. 2005 Jun 15;103(12):2584-9
15887220
Clin Cancer Res. 2000 Sep;6(9):3719-28
10999766
J Clin Oncol. 2004 Jun 1;22(11):2108-21
15169797
Annu Rev Biochem. 1998;67:425-79
9759494
EMBO J. 1996 Aug 15;15(16):4182-93
8861947
Genes Dev. 1999 Aug 1;13(15):1899-911
10444588
EMBO J. 1998 Dec 15;17(24):7151-60
9857172
Nat Rev Cancer. 2004 May;4(5):349-60
15122206
Blood. 2008 Nov 1;112(9):3835-46
18633129
Biochem Pharmacol. 2005 May 15;69(10):1421-32
15857606
Hematology Am Soc Hematol Educ Program. 2000;:147-165
11701540